“…Patients with severe allergic asthma often experience a significant decline in lung function. Despite the fact that some studies have not found a significant improvement in forced expiratory volume in 1 s (FEV1) after the initiation of omalizumab [118,166,[183][184][185][186][187][188][189], the majority of the studies have exhibited a significant improvement in FEV1 after the initiation of omalizumab in asthmatic patients both as a whole [17,29,32,33,59,60,67,73,81,86,119,152,153,158,162,173,[190][191][192][193][194][195][196][197][198], and in specific groups such as children [199], obese patients [200], patients with fixed airway obstruction [201], patients with various co-morbidities [202], and even non-atopic patients with asthma [87]. Similar improvements after the initiation of omalizumab have also been observed in forced vital capacity (FVC) [33,203], FEV1/FVC ratio [59,73], peak expiratory flow (PEF) [19,86,…”